Silver Oak Advisory Group Inc. Sells 27 Shares of Eli Lilly and Company (NYSE:LLY)

Silver Oak Advisory Group Inc. lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 4.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 620 shares of the company’s stock after selling 27 shares during the quarter. Silver Oak Advisory Group Inc.’s holdings in Eli Lilly and Company were worth $549,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Glaxis Capital Management LLC bought a new position in Eli Lilly and Company during the 3rd quarter worth approximately $443,000. Darwin Wealth Management LLC bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at about $378,000. Anthracite Investment Company Inc. acquired a new stake in Eli Lilly and Company during the third quarter worth approximately $2,215,000. First Horizon Advisors Inc. increased its holdings in Eli Lilly and Company by 0.3% in the third quarter. First Horizon Advisors Inc. now owns 10,057 shares of the company’s stock worth $8,910,000 after purchasing an additional 26 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Eli Lilly and Company by 6.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 58,044 shares of the company’s stock valued at $51,424,000 after buying an additional 3,644 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.7 %

Eli Lilly and Company stock opened at $735.00 on Wednesday. The firm has a 50 day moving average price of $875.60 and a 200-day moving average price of $870.81. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53. The company has a market capitalization of $697.75 billion, a P/E ratio of 78.88, a P/E/G ratio of 2.82 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter in the previous year, the company posted $0.10 EPS. Eli Lilly and Company’s revenue for the quarter was up 20.4% on a year-over-year basis. As a group, equities analysts predict that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Morgan Stanley restated an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. BMO Capital Markets lifted their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Finally, Guggenheim increased their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.